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Proper segregation of chromosomes depends on a functional spindle assembly checkpoint
(SAC) and requires kinetochore localization of the Bub1 and Mad1/Mad2 checkpoint proteins.
Several aspects of Mad1/Mad2 kinetochore recruitment in human cells are unclear and in
particular the underlying direct interactions. Here we show that conserved domain 1 (CD1) in
human Bub1 binds directly to Mad1 and a phosphorylation site exists in CD1 that stimulates
Mad1 binding and SAC signalling. Importantly, fusion of minimal kinetochore-targeting Bub1
fragments to Mad1 bypasses the need for CD1, revealing that the main function of Bub1 is to
position Mad1 close to KNL1 MELTrepeats. Furthermore, we identify residues in Mad1 that are
critical for Mad1 functionality, but not Bub1 binding, arguing for a direct role of Mad1 in the
checkpoint. This work dissects functionally relevant molecular interactions required for
spindle assembly checkpoint signalling at kinetochores in human cells.
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A
prerequisite for life is the equal distribution of genetic
information to the new daughter cells and this requires
that the genome is accurately duplicated and subsequently
distributed to new cells. Accurate segregation of sister chromatids
during cell division depends on the spindle assembly checkpoint
(SAC), which in response to improper attachments between
kinetochores and microtubules generates a diffusible ‘wait
anaphase’ inhibitor1–3. This inhibitor is the mitotic checkpoint
complex (MCC) composed of the Mad2 and BubR1–Bub3
checkpoint proteins bound to Cdc20, the mitotic co-activator of
the anaphase-promoting complex (APC/C)4. The MCC potently
inhibits the APC/C-Cdc20 complex and this prevents the
entry into anaphase, hereby providing time for proper bi-
orientation of all sister chromatids. Once all kinetochores are
attached to microtubules, the production of the MCC ceases and,
in addition, the existing MCC is disassembled resulting in active
APC/C-Cdc20 and the progression into anaphase.
The essential components of the SAC were identiﬁed in the
early 1990s and include the mitotic arrest deﬁcient (Mad)
proteins Mad1, Mad2 and Mad3 (BubR1 in humans) as well as
the budding uninhibited by benzimidazole proteins (Bub) Bub1
and Bub3 (refs 5,6). Bub1 and BubR1 are in a stable complex
with Bub3, while Mad2 exists in a stable complex with Mad1 and
as free Mad2 (refs 7,8). In addition to these structural
components, checkpoint signalling also depends on at least
three kinases namely cyclin-dependent kinase 1 (Cdk1), Aurora B
and monopolar spindle 1 (Mps1)9–16. However, only a few
phosphosites on kinetochore and checkpoint proteins that
directly regulate the SAC have been identiﬁed.
A major question in the ﬁeld is how the checkpoint proteins are
recruited to kinetochores and how this stimulates the generation of
the MCC. It is clear that all checkpoint proteins localize dynamically
to unattached kinetochores, as does Cdc20. This localization
depends on a large outer kinetochore complex composed of the
KNL1-Zwint complex, the Mis12 complex and the Ndc80 complex
(collectively referred to as the KMN network)17–21. The KNL1
protein is a direct receptor for the Bub1–Bub3 and BubR1–Bub3
complexes because the phosphorylation of so-called Met–Glu–Leu–
Thr (MELT) repeats in KNL1 by the Mps1 kinase generates binding
sites for Bub3 (refs 22–30). Bub1 and BubR1 both contain short
linear motifs referred to as ABBA motifs (also known as Phe-box or
A-box) that act to localize Cdc20 to kinetochores with the removal
of the ABBA motif in Bub1 having a more pronounced effect on
SAC signalling31–36.
The exact mechanism behind recruitment of the Mad1/Mad2
complex to kinetochores in humans has not been established, but
given the central role of this complex for SAC signalling this is
crucial to understand. This contrasts the situation in budding
yeast and worms where a direct interaction between Mad1
and Bub1 has been shown to localize Mad1/Mad2 to
kinetochores37–39. In budding yeast, this Mad1–Bub1
interaction is stimulated by Mps1 phosphorylation of multiple
sites in a central unstructured region in Bub1 spanning residues
369–608 (ref. 37). Interestingly, in worms it is the kinase domain
of Bub1 that binds Mad1 directly suggesting that the Mad1/Mad2
complex can be recruited to kinetochores by different
mechanisms38. In human cells a direct interaction between
Mad1 and Bub1 stimulated by Mps1 was recently described40,41
and consistently Bub1 has been proposed to scaffold the assembly
of SAC complexes on MELT repeats30. In addition the
Rod-Zwilch-ZW10 (RZZ) complex is required for Mad1/Mad2
kinetochore localization and checkpoint signalling in higher
eukaryotes33,42–44. The exact contribution of Bub1 and the RZZ
complex is still to be fully dissected.
To further our understanding of Mad1/Mad2 kinetochore
recruitment and the function of Bub1 in human cells, we here
focus on the molecular function of conserved domain (CD1) in
Bub1 that is essential for SAC signalling in both humans and
yeast45,46. We show here that CD1 is required for a
phosphoregulated direct interaction between human Bub1 and
Mad1 and that disturbance of this interaction is detrimental to
the SAC. In line with this we can bypass the requirement for CD1
by fusing minimal kinetochore targeting Bub1 fragments to
Mad1, suggesting that the main function of Bub1 in SAC
signalling is to localize Mad1 correctly at kinetochores.
Interestingly, residues in a C-terminal globular domain of
Mad1 are still required for SAC signalling when Bub1 and
Mad1 are fused arguing that Mad1 has additional functions in the
SAC. In conclusion, we establish a direct interaction between
human Bub1 and Mad1, identify a critical phosphorylation site
required for this interaction and identify the key function of the
interaction. We hereby provide novel insight into Mad1/Mad2
kinetochore localization in human cells by Bub1 and propose that
precise positioning of Mad1/Mad2 close to KNL1 MELT repeats
is critical for checkpoint signalling.
Results
Bub1 conserved domain 1 is essential for SAC signalling. The
Bub1 checkpoint protein contains different motifs that have been
implicated in its function including CD1 and the ABBA motif
(Fig. 1a). The function of CD1 is unclear, while the ABBA motif is
required for recruiting a fraction of Cdc20 to kinetochores
(we will discuss recent parallel data on CD1 (ref. 40) from the Yu
lab published during the reviewing of this manuscript in the
discussion; Supplementary Fig. 1 and refs 31,32). The removal of
CD1 did not affect Cdc20 kinetochore localization suggesting
that CD1 performs a different function in the checkpoint
(Supplementary Fig. 1). To directly compare the importance of
these two motifs, we ﬁrst established a Bub1 RNAi rescue system
in HeLa cells (Fig. 1b). Compared to control treated cells that
had a median mitotic duration of 555min in the presence of low
dose of nocodazole, Bub1 RNAi-treated cells only spent 285min
in mitosis, revealing a requirement for Bub1 for efﬁcient
checkpoint signalling (Fig. 1c,d). By co-transfecting Bub1-deple-
ted cells with a RNAi-resistant plasmid encoding Bub1 residues
1–553 tagged with Venus, which we have previously shown to
fully support SAC signalling in MEFs devoid of endogenous Bub1
(ref. 33), we could restore mitotic duration to the same level as in
control cells. Bub1 1–553 localized efﬁciently to kinetochores as
did all constructs in this study unless otherwise speciﬁed.
Only cells expressing similar ﬂuorescent intensities were analysed
and quantiﬁed (Fig. 1d; Supplementary Fig. 1). To conﬁrm the
SAC deﬁciency achieved by live cell imaging, we analysed the
ability of Mad2 to interact with Cdc20, BubR1 and the APC/C
under these conditions by immunoprecipitation of Mad2 and
found that Bub1 RNAi resulted in reduced interaction and that
this could be fully rescued by expression of Bub1 1–553 (Fig. 1e,f;
Supplementary Fig. 11), revealing a role of Bub1 in efﬁcient MCC
formation.
Next, we used our Bub1 RNAi complementation system to
directly compare the importance of CD1 and the ABBA motif. We
transfected Bub1-depleted cells with Bub1 1–553DCD1 lacking the
entire CD1 (residues 458–476) or with Bub1 1–529 that removes
critical residues from the ABBA motif (Fig. 1a). Cells complemented
with Bub1 1–529 had a mitotic duration of 370min, while cells
complemented with Bub1 1–553DCD1 only arrested for 110min
(Fig. 1c,d). A similar short mitotic timing was observed in Bub1
1–529DCD1 expressing cells indicating no additional effect of
removing the ABBA motif when CD1 was deleted.
A likely explanation for the inhibitory effect of Bub1 proteins
lacking CD1 is that they do not support any SAC signalling and
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compete with remaining endogenous Bub1 for binding to KNL1
similarly to what has previously been observed with another Bub1
mutant (Bub1 1–311)47,48. Indeed, a Bub1 mutant lacking both
the CD1 and with mutations in the Bub3 binding domain
(referred to as DGLEBS) did not localize to kinetochores and
showed a very similar mitotic timing as Bub1 RNAi treated cells
(Fig. 1c; Supplementary Fig. 2). The mitotic timing of 110min
observed in Bub1 1–553DCD1 expressing cells thus likely
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represents the timing in cells where endogenous Bub1 is fully
inactivated by a combination of RNAi depletion and competition
for KNL binding from non-functional Bub1.
The conclusion from these experiments is that CD1 is essential
for Bub1 functionality and its removal results in inactive forms of
Bub1. Therefore, we set out to understand the function of CD1.
Phosphorylation sites in CD1 are required for the SAC.
We ﬁrst analysed the importance of different residues in CD1
for a functional checkpoint. The CD1 contains two reported
phosphorylation sites, Ser459 and Thr461 (refs 49,50). Following
the phosphorylation sites is a region that is predicted to form an
alpha helix51 and indeed circular dichroism spectra of CD1
peptides conﬁrmed the possibility of an alpha helix (Fig. 1a;
Supplementary Fig. 3).
We mutated either phosphorylation sites or hydrophobic
residues in CD1 and investigated whether this resulted in inactive
forms of Bub1 1–553 arguing that they are critical for Bub1
function. All Bub1 CD1 mutants tested localized to kinetochores
similar to wild-type Bub1 arguing that they are correctly folded
and bind Bub3.
Mutation of Ser459 or Thr461 to Ala inactivated Bub1 showing
that these two residues are critical for CD1 functionality (Fig. 1g;
Supplementary Fig. 4A). For comparison, mutation of another
reported phosphorylation site just outside of the CD1 region,
Thr452, had only a minor effect on SAC signalling. Cells
complemented with Bub1 having phosphomimicking mutations,
Ser459 to Glu or Thr461 to Asp restored checkpoint activity
arguing that phosphorylation of Ser459 and Thr461 in Bub1 is
important for SAC signalling. Mutation of hydrophobic residues
Ile471 or Met–Phe–Gln (residues 474–476) to charged residues
resulted in Bub1 constructs that were as defective as deletion of
the entire CD1.
To investigate whether the phosphorylation of Bub1 occurs at
kinetochores in vivo, we generated a phosphospeciﬁc antibody
against a peptide phosphorylated on both Ser459 and Thr461
(referred as pSpT in Fig. 2). The antibody stained kinetochores of
nocodazole arrested cells, but when cells were depleted of Bub1 or
treated with lambda phosphatase before staining the kinetochore
staining disappeared (Fig. 2). Furthermore, expression of Bub1
1–553 in Bub1-depleted cells restored the kinetochore staining,
but this was absent when Ser459 was mutated and largely reduced
when Thr461 was mutated further conﬁrming the speciﬁcity of
the antibody (Fig. 2d,e). So far, we do not know the relative
contribution of the Ser459 and Thr461 phosphorylation sites to
the speciﬁcity of the antibody. In undisturbed mitotic cells,
the antibody stained kinetochores of cells in prometaphase,
but reduced kinetochore staining was observed when cells were
in metaphase and no staining was observed on anaphase
kinetochores (Fig. 2c).
To identify mitotic kinases able to phosphorylate Bub1 on
Ser459 and Thr461 we performed in vitro phosphorylation assays
with candidate kinases. The Ser459 phosphorylation site matched
a Cdk1 consensus, while the Thr461 did not resemble any
known kinase consensus. However, given the fact that Mps1
phosphorylates the corresponding Thr455 site in budding yeast
Bub1 (ref. 37) we suspected that Mps1 might be the kinase that
phosphorylates Thr461. We incubated puriﬁed GST-Bub1
encompassing amino acids 425–500 with either puriﬁed
Cdk1-Cyclin B1 or Mps1 and analysed the samples by mass
spectrometry. Addition of Cdk1-Cyclin B1 resulted in
phosphorylation of Ser459 and Thr461,while addition of Mps1
resulted in phosphorylation of Thr461 but no phosphorylation on
Ser459, supporting that these kinases are able to phosphorylate
functional relevant phosphorylation sites in CD1 (Supplementary
Fig. 4B).
In conclusion, phosphorylation of functional relevant sites
in CD1 occurs at kinetochores in vivo and the in vitro
phosphorylation assays indicate Cdk1–Cyclin B1 and Mps1 as
possible mitotic kinases able to phosphorylate CD1. In addition,
hydrophobic residues in CD1 are also critical for functionality
of Bub1.
Bub1 conserved domain 1 is required for direct Mad1 binding.
We speculated that CD1 might engage in a protein-protein
interaction that is critical for checkpoint signalling. Mad1
appeared to be the only core component of the checkpoint
for which we could see an effect of removing the CD1 on its
kinetochore levels (Supplementary Fig. 1 for Cdc20 and ref. 33 for
BubR1, Mad1). However, an interaction between human Mad1
and Bub1 cannot be detected in immunoprecipitation
experiments52. To determine whether there was an interaction
between human Mad1 and Bub1, we ﬁrst developed an assay for
looking at transient and/or weak Mad1 interactions in vivo.
To this end, we used a proximity-dependent ligation assay
(BioID53) based on a fusion of the promiscuous biotin ligase BirA
to either the N terminus or the C terminus of Mad1. In stable cell
lines expressing BirA–Mad1 or Mad1–BirA at close to
endogenous levels the kinetochore was biotinylated upon
addition of biotin to the media, and we puriﬁed the
biotinylated proteins using streptavidin beads under stringent
conditions (Fig. 3a–c; Supplementary Fig. 5A,B). The puriﬁcation
and detection of biotinylated proteins were highly robust and
we detected multiple Mad1 peptides upon addition of biotin,
as expected (Supplementary Fig. 5C). Using a quantitative mass
spectrometry SILAC approach allowed us to compare the
proximity of proteins to the N terminus versus the C terminus
of Mad1. The SILAC ratio of BirA-Mad1 to Mad1-BirA was one
with this approach. This showed that Bub1, BubR1 and Cdc20
were more efﬁciently labelled with biotin in the Mad1-BirA
Figure 1 | The CD1 domain is essential for Bub1 function. (a) Schematic of Bub1 primary structure with the position of GLEBS, CD1, ABBA motif and kinase
domain indicated. Numbers on top refer to residue numbers and amino acid sequence of CD1 and surrounding residues is above the scheme. The residues
mutated in this study are indicated in red. Reported human Bub1 phosphorylation sites are indicated above with a P and the region of CD1 forming a
potential alpha helix is indicated. (b) Outline of synchronization and RNAi depletion protocol used in this study. (D: day). (c) Bub1 RNAi and rescue with the
indicated Bub1 RNAi-resistant constructs was performed in HeLa cells using the protocol outlined in b). A low dose of nocodazole was used for the live cell
imaging and the time from nuclear envelope breakdown (NEBD) to exit was measured in single cells and indicated by the circles. The number of cells
analysed per condition and the median mitotic timing (red line) are indicated above each condition. A Mann–Whitney test was used for statistical
comparison of the different samples. (****Pr0.0001, NS: non signiﬁcant). (d) Representative still images for Venus-Bub1 1–553 and Venus-Bub1 1–553
DCD1. Scale bar, 5 mm. (e) Parental HeLa cells or stable HeLa cells expressing inducible Venus-Bub1 1–553 were treated twice with RNAi against luciferase
as control or Bub1 before treatment with nocodazole (200ngml 1). Mitotic cells were collected and Mad2 immunoprecipitated using a pan-Mad2
antibody and the level of associated Cdc20, BubR1 and APC7 was determined by quantitative western blot. Representative of two independent
experiments. (f) Quantiﬁcation of experiment shown in e. (g) HeLa cells were treated similarly as c. Live cell imaging was performed in the presence of low
dose of nocodazole and the time from NEBD to exit was measured in single cells. Results are presented as c. A Mann–Whitney test was used for statistical
comparison of the different samples. (****Pr0.0001).
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expressing cells, suggesting that they were closer to the
C-terminus of Mad1 (Fig. 3a–c). In contrast, a number of inner
nuclear pore proteins were more efﬁciently biotinylated in the
BirA-Mad1 expressing cell line in agreement with the reported
interaction of the Mad1 N-terminus and the nucleoporin TPR54.
Despite Mad2 being a stable binding partner of Mad1 we did not
detect labeling of Mad2, which can be due to lack of lysine
residues that are optimally positioned to be labelled by BirA fused
to Mad1.
Given the strong biotinylation of Bub1 in the Mad1-BirA cell
line we tested whether we could detect a direct interaction
between Bub1 and the C terminus of Mad1. We puriﬁed
FLAG-Bub1 146–553/Bub3 and FLAG-Bub1 146–553
DCD1/Bub3 complexes from HEK293 cells and Strep-Mad1
597–718 from bacteria, which forms a stable Mad1 dimer55.
We determined the exact molecular mass of all recombinant
Mad1 complexes used in this study by multi-angle light scattering
analysis, which conﬁrmed their predicted composition.
This Mad1 C-terminal fragment was incubated with Bub1
146–553/Bub3 complexes before being captured by a Strep
afﬁnity resin and following washing and elution the binding of
Bub1 was analysed by blotting for FLAG. We could detect
binding of FLAG-Bub1 146–553/Bub3 to Mad1 while the removal
of DCD1 prevented this interaction (Fig. 3d,e).
To further investigate a possible direct interaction between
Mad1 and CD1, we used surface plasmon resonance technology.
We immobilized a biotinylated CD1 peptide (residues 449–480)
as well as a control CD1 peptide with mutations of residues
461–465 to Ala on the surface of the chip and tested the binding
to Mad1 597–718 (Fig. 4; Supplementary Fig. 6). To achieve a
more efﬁcient synthesis of CD1 peptides and in particularly of the
phosphorylated peptides we used norleucine (Nle) instead of
methionine (Met) but we cannot exclude that Mad1 will have a
different afﬁnity for peptides containing methionine. We could
only detect a weak interaction to the unphosphorylated CD1
peptide (Kd¼ 304 mM) and no binding to the control peptide.
Given that Ser459 and Thr461 phosphorylation was critical
for Bub1 functionality in vivo we tested if they affected Mad1
597–718 binding. A CD1 peptide with Thr461 phosphorylated
showed a 10-fold stronger binding to Mad1 with a Kd of 32 mM,
while phosphorylation of S459 did not stimulate the interaction
(Fig. 4a). When both Ser459 and Thr461 where phosphorylated
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we measured a Kd of 16 mM showing that Thr461 is the
phosphorylation site contributing the most to Mad1 binding.
A recombinant tetrameric Mad1(485–718)/Mad2 complex also
bound to the CD1 peptide phosphorylated on Thr461 with a Kd
of 72 mM (Fig. 4b). As the Mad1 RLK motif is required for
binding Bub1 in budding yeast in vivo39, we tested whether this
motif was required for direct binding to CD1 phosphorylated on
Thr461. Mad1 597–718 RLK/AAA migrated at the same position
on a size exclusion column as the wild-type protein arguing that
the mutations did not affect folding. However, Mad1 597–718
RLK/AAA showed no binding to the phosphorylated CD1
peptide (Fig. 4b). We furthermore analysed the binding of
Mad1 597–718 to CD1 peptides harboring the Ile471Asp and
MFQ/RRK (residues 474–476) mutations with Thr461 being
phosphorylated. Both mutations blocked the binding of Mad1 to
CD1 showing that these hydrophobic residues are important for
the interaction (Fig. 4a,c).
These results reveal a direct interaction between the C terminus
of human Mad1 and the CD1 of Bub1. The interaction is
stimulated by phosphorylation of Bub1 on Thr461 and requires
the RLK motif of Mad1.
Fusion of Mad1 and Bub1 bypasses the requirement for CD1.
In live cell experiments we observed that Venus-Mad1 RLK/AAA
failed to localize to kinetochores supporting the notion that a
direct Bub1-Mad1 interaction facilitates Mad1/Mad2 kinetochore
localization in human cells (Supplementary Fig. 7A). In addition
to localizing Mad1/Mad2 to kinetochores we considered the
possibility that Bub1 CD1 might have additional functions in the
checkpoint. This possibility was suggested by observations in
ﬁssion yeast where the CD1 domain is still required for the
checkpoint when Mad1 is tethered to kinetochores45. To test this,
we fused Mad1 residues 485–718, a region of Mad1 that has
previously been shown to support SAC signalling in vivo56, to the
N terminus of Bub1 1–553 DCD1 (fusion protein referred to as
Mad1—Bub1DCD1). All fusion constructs used here have a
ﬂexible six amino-acid linker (GSGSGS) between the two
proteins. In our Bub1 RNAi system Mad1—Bub1DCD1
fully restored SAC signalling (Fig. 5a; Supplementary Fig. 7B).
If we mutated the Bub3 binding domain in this fusion protein it
no longer localized to kinetochores and failed to support SAC
signalling (Fig. 5a; Supplementary Fig. 7B; note that this construct
has a negative effect on the checkpoint likely due to Mad1
sequestering soluble Mad2). If we fused Mad2 to the C terminus
of Bub1 1–553 DCD1 (Bub1 DCD1-Mad2) this also bypassed the
requirement for CD1 in our Bub1 RNAi assay (Fig. 5b;
Supplementary Fig. 8A). Consistently, we could detect Mad1 in
immunopuriﬁcations of the Bub1 DCD1-Mad2 fusion protein
arguing that Mad1 is indirectly recruited via Mad2 in this fusion
protein (Supplementary Fig. 8B). The ability of Bub1DCD1-Mad2
to support SAC signalling in the absence of endogenous Bub1
required that the dimerization interface of the tethered Mad2
was intact because mutating Arg133 and Gln134 to glutamic acid
and alanine (Mad2 RQ/EA) resulted in an inactive construct
(Fig. 5b). This is consistent with the Mad2 template model for
Mad2 activation57.
Surprisingly, fusion of Mad1 485–718 to amino acids 1–280
of Bub1 (Mad1–Bub1 1–280) was sufﬁcient to support checkpoint
activity when endogenous Bub1 was depleted (Fig. 5a). Bub1
1–280 contains the kinetochore targeting part of Bub1 in form of
the TPR domain and the Bub3 binding region and the ability of
Mad1–Bub1 1–280 to rescue Bub1 depletion argues that the main
function of Bub1 in SAC signalling is to properly localize Mad1 at
kinetochores.
To rule out that artiﬁcial localization of Mad1 to KNL1
bypassed the requirement for Bub1 in the checkpoint we fused
Mad1 485–718 to a minimal KNL1 protein encompassing four
MELT repeats (amino acids 1000–1200) and the kinetochore-
targeting domain of KNL1 (amino acids 1834–2316). Although
this construct enhanced SAC signalling in nocodazole-arrested
cells this was fully dependent on Bub1 as Bub1 depletion
c
Affinity of CD1 peptides for Mad1
Peptide
CD1 WT
CD1 pS459
CD1 pT461
VQATPSKVQPSPTVHTKEALGFI(Nle)N(Nle)FQAPTLW
VQATPSKVQPSPTVHTKEALGFI(Nle)N(Nle)FQAPTLW
VQATPSKVQPSPTVHTKEALGFI(Nle)N(Nle)FQAPTLW 298  M
32   M
μ
μ
304  Mμ
CD1 control VQATPSKVQASPAAAAAEALGFI(Nle)N(Nle)FQAPTLW no binding
CD1 pS459/pT461 VQATPSKVQPSPTVHTKEALGFI(Nle)N(Nle)FQAPTLW 16  μM
CD1 I471D VQATPSKVQPSPTVHTKEALGFD(Nle)N(Nle)FQAPTLW no binding
CD1 MFQ/RRK VQATPSKVQPSPTVHTKEALGFI(Nle)NRRKAPTLW no binding
KD = 32 μM
KD = 72 μM
Mad1 RLK/AAA
Mad1/Mad2
Mad1
Concentration (M)
R
no
m
 (%
)
KD = 32 μM
KD = 304 μM
KD = 298 μM
pS459
WT
pS459/pT461
Control
KD = 16 μM
MFQ/RRK
I471D
pT461
0 1e–4 2e–4 3e–4 4e–4 5e–4
R
no
m
 (%
)
Concentration (M)
0 1e–4 2e–4 3e–4 4e–4 5e–4
a b
20
40
60
80
100
20
40
60
80
100
Sequence KD
Figure 4 | Direct binding of Mad1 to CD1 peptide. (a) SPR steady-state responses for control, WT, pS459, pT461, pS459/pT461, I471D, MFQ/RKK
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signiﬁcantly reduced the time cells spent in mitosis (Fig. 5c;
Supplementary Fig. 9). Thus, the ability of Mad1–Bub1 1–280 to
replace Bub1 function is not simply a result of localizing Mad1 to
KNL1.
From this we hypothesize that Mad1 has to be positioned
accurately within the kinetochore to stimulate SAC signalling and
that Bub1 through its CD1 brings Mad1 close to KNL1 MELT
repeats a function recapitulated by the minimal Mad1–Bub1
1–280.
Mad1 has additional functions in the SAC. The lab of Silke Hauf
and ours previously reported that Mad1 has a direct role in the
checkpoint independently from recruiting Mad2 to kinetochores.
This function depends on conserved residues in the C terminus of
Mad1 namely Glu710, Phe712 and Arg714 (refs 45,52).
We previously speculated that these Mad1 residues could be
binding Bub1 and thus be required for Mad1 to be fully
functional in SAC signalling.
To investigate this, we ﬁrst tested the role of these
Mad1 residues in binding Bub1. We measured the ability of
recombinant Mad1 (597–718) Glu710Ala/Phe712Ala to bind the
CD1 peptide phosphorylated on Thr461. This revealed that the
Mad1 mutant had the same afﬁnity towards phosphorylated CD1
as wild type Mad1 (597–718; Fig. 6a). Consistently, if we mutated
Glu710, Phe712 and Arg714 to Ala in Mad1-BirA (MAD1
EFR/AAA) this did not affect the biotinylation of Bub1 and
KNL1, further supporting that these residues are not required for
Bub1 binding (Fig. 6b; Supplementary Fig. 10). However, when
we mutated Glu710 and Phe712 to Ala in the Mad1–Bub1DCD1
fusion we found that this mutant was less efﬁcient in supporting
SAC signalling (Fig. 6c; Supplementary Fig. 7). This argues that
Mad1 has an important function in the checkpoint in addition to
interacting with Mad2 and Bub1.
Discussion
The kinetochore and checkpoint proteins form a complex set of
interactions that facilitate the generation of the ‘wait anaphase’
signal in the form of the MCC. Understanding SAC signalling
requires the elucidation of the molecular interactions between
checkpoint components. Here we present experimental data,
which unequivocally show a direct Mad1–Bub1 interaction in
human cells in agreement with recent studies showing an Mps1
stimulated interaction between the human checkpoint pro-
teins40,41. The Mad1 RLK/AAA mutant is unable to bind
directly to Bub1 and fails to localize efﬁciently to kinetochores,
arguing that a direct Bub1-Mad1 interaction is important
for Mad1 kinetochore localization. This does not exclude
contribution from other components such as the RZZ complex
that could stabilize the Mad1–Bub1 interaction. Our results
suggest that Bub1 has an important role in positioning the
Mad1/Mad2 complex in proximity of MELT repeats on KNL1
and we favor that this is to bring it into proximity of Cdc20 and
BubR1 to promote MCC formation (Fig. 6d). We propose this
model based on a number of observations. First, fusion of the
kinetochore-targeting region of Bub1 (Bub1 1–280) to Mad1
generates a minimal construct that supports SAC signalling when
endogenous Bub1 is depleted. Second, we ﬁnd that the fusion of
Mad1 to KNL1 is not sufﬁcient to bypass the requirement for
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Bub1 and in agreement with this, the CD1 is still required in
ﬁssion yeast when Mad1 is tethered to kinetochores45.
An interesting aspect uncovered here is that the CD1 needs to
be phosphorylated to function in line with observations from
budding and ﬁssion yeast37,45,58. We show that this occurs at
kinetochores in prometaphase and our in vitro phosphorylation
assays implicate Cdk1 and Mps1 as possible kinases. Recent work
from the Yu lab suggests that Cdk1 phosphorylates Ser459 to
allow subsequent phosphorylation of Thr461 by Mps1 (ref. 40).
We have not extensively explored this and our data does not
exclude this idea, but we also see that Mps1 can directly
phosphorylate Thr461 in vitro as observed in budding yeast37.
Our in vitro phosphorylation assays with Cdk1-Cyclin B1 suggest
an alternative possibility namely that Cdk1 phosphorylates both
sites and it has been shown that Cdk1 can phosphorylate
non-Ser/Thr-Pro sites. Indeed, Thr461 has surrounding residues
that are favourable for non-Ser/Thr-Pro sites including a Lysine
residue in the þ 4 position59.
We show that the function of Thr461 phosphorylation is to
facilitate Mad1 binding, which is fully consistent with recent data
from the Yu lab40 and the work from budding yeast37. Elegant
work using budding yeast proteins revealed that a large internal
Bub1 fragment phosphorylated by Mps1 can bind Mad1/Mad2
directly, but the exact region of Bub1 and which phosphorylation
sites bind to Mad1 were not identiﬁed37. Our result and that of
the Yu lab support that the key contact site of budding yeast
Mad1 is likely CD1, explaining its conservation37,39,45,46. We note
that worm Bub1 has lost CD1 potentially explaining why Mad1
binds the kinase domain.
In addition to the CD1 phosphorylation sites, hydrophobic
residues that might constitute part of an alpha-helical segment of
CD1 are also critical for Bub1 function and Mad1 binding. An
interesting idea is that the Thr461 phosphorylation binds to the
RLK motif and the hydrophobic residues from the alpha helical
segment of CD1 interacts with the coiled-coil part of Mad1.
Another important function of Bub1 is to localize a fraction of
Cdc20 to kinetochores through its ABBA motif31,32. In the
Mad1–Bub1 fusions we do not see a requirement for the ABBA
motif, while we observe this in Bub1 alone. This is likely due to a
redundancy of the ABBA motif in Bub1 and the C-terminal
ABBA motif in BubR1 and that both contribute to localization of
Cdc20 to kinetochores31,34. Since Mad1 binds CD1, it would
b
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position the Mad1/Mad2 complex close to Cdc20 bound to the
ABBA motif in Bub1, hereby facilitating Mad2-Cdc20 complex
formation and recent in vitro reconstitution data support
this40,41. This would explain why removal of the ABBA motif
from Bub1 results in reduced checkpoint activity. However, the
ABBA motif of Bub1 is not as critical for Bub1 functionality as
the CD1 and we favour this is due to BubR1 recruiting Cdc20 as
well.
Finally, this work provides novel insight into our previous
observations of a direct role of Mad1 in the checkpoint52. Since
mutations in the C-terminal globular part of Mad1 are still critical
for Mad1 functionality in the Mad1–Bub1 fusion, this argues that
these residues are important for an aspect of Mad1 function
unrelated to Bub1 binding. Consistent with this is the
recent in vitro reconstitutions of MCC formation showed that
the Mad1/Mad2 complex acts catalytically when phosphorylated
by Mps1 even in the absence of Bub1 (refs 40,41). Interestingly,
Mps1 phosphorylates Ser713 and Thr716, which are close to
Glu710 and Phe712 that we have mutated. One possibility is that
these mutations prevents binding of Cdc20 to the Mad1 C
terminus40.
In conclusion, we dissect a direct phosphoregulated interaction
between Bub1 and Mad1 and uncover its role in the checkpoint in
human cells.
Methods
Cell culture techniques. HeLa cells (ATCC) were cultivated in DMEM medium
(Invitrogen) supplemented with 10% fetal bovine serum and antibiotics. Cells were
synchronized by thymidine (2.5mM) the day before co-transfection with siRNA
oligos against Bub1 (100 nM as ﬁnal concentration) and corresponding plasmids by
Lipofectamine 2000 (Life Technologies). RNAi oligos targeting Bub1 (50-GAGU-
GAUCACGAUUUCUAA-30) or luciferase (50-CGUACGCGGAAUACUUCGA-30),
were used for RNAi depletions. Thymidine was added again 12 h later after
transfection. A second RNAi was performed during the second thymidine block.
Twenty four hours later, the cells were released from thymidine block. Filming or
ﬁxation was performed when cells entered mitosis.
For SILAC labelling, HeLa cells were grown in SILAC DMEM medium
(Invitrogen) supplemented with 10% dialysed FBS, L-glutamine, penicillin/
streptomycin and isotope labelled arginine and lysine. L-lysine and L-arginine
(Sigma) were used for light culture. L-lysine 4,4,5,5-D4 and L-arginine–U-13C6,
or L-lysine-U-13C6-15N2 and L-arginine–U-13C6-15N4 (Cambridge Isotope
Laboratories) were used for medium or heavy culture.
Cloning. Venus-Bub1 1–553 and all its variants were cloned into N-Venus
pcDNA5/FRT/TO plasmid with KpnI and NotI sites on 50 and 30 ends.
Venus- Mad1–Bub1 1–553 DCD1 was cloned by inserting Mad1 (cDNA coding for
485-718aa) into Venus-Bub1 at KpnI site while Venus-Bub1 1–553DCD1-Mad2
was cloned by inserting full length Mad2 using NotI. pGEX Bub1 425–500 was
cloned by amplifying this fragment of Bub1 by PCR and cloning it into BamHI/
NotI of pGEX. Full-length Mad1 was PCR ampliﬁed and cloned into pcDNA5/
FRT/TO-BirA C-term using KpnI and BamHI or pcDNA5/FRT/TO-BirA N-term
using BamHI and NotI to generate Mad1-BirA or BirA-Mad1 fusion constructs.
Indicated point mutations were introduced into Mad1 using a QuickChange PCR
mutagenesis strategy. Details of cloning will be provided upon request.
Puriﬁcation of biotinylated protein complexes. Stable HeLa cell lines expressing
the indicated Mad1 BirA fusion proteins were exposed to 0.1 ngml 1 doxycycline
for 18 h to obtain near endogenous Mad1 expression levels. Cells were arrested in
mitosis by a single thymidine block and subsequent nocodazole (150 ngml 1)
treatment for 16 h. Biotinylation of proximity interactors was induced by the
addition of a ﬁnal concentration of 25 mM of biotin simultaneously with the
addition of nocodazole. Mitotic cells were collected and washed three times in PBS
before lysed in RIPA buffer (50mM Tris pH 7.5, 150mM NaCl, 1mM EDTA, 1%
Nonidet P-40, 0.25% Na-deoxycholate, 0.1% SDS) containing protease inhibitors
(Roche). Cell lysate was clariﬁed by centrifugation and incubated overnight at 4 C
with High Capacity Streptavidin Resin (Thermo Scientiﬁc). Streptavidin beads were
washed once with RIPA buffer followed by two washes with water containing 2%
SDS and a ﬁnal wash with RIPA buffer. Biotinylated proteins were eluted from the
streptavidin beads with 2 Laemmli LDS sample buffer containing 1mM of biotin
before separated on 4–12% Bis-Tris NuPage gels (Life technologies). After
separation, proteins were either examined by western blot or processed for
quantitative SILAC mass spectrometry (see below).
Mass spectrometric analysis. Cells were collected and biotinylated protein
complexes puriﬁed as described above. The indicated LDS sample buffer eluates
were combined and resolved by SDS–PAGE gel electrophoresis. The Coomassie-
stained gel was cut into slices, reduced with 1mM DTT, alkylated with 5mM
chloroacetamide, digested using modiﬁed sequencing grade trypsin (Sigma) and
loaded on to C18 stage tips before mass spectrometric analysis.
All mass spectrometry experiments were performed on a nanoscale EASY-nLC
1000 UHPLC system (Thermo Fisher Scientiﬁc) connected to an Orbitrap
Q-Exactive Plus equipped with a nanoelectrospray source (Thermo Fisher
Scientiﬁc). Each sample was eluted off the StageTip, auto-sampled and separated
on a 15 cm analytical column (75 mm inner diameter) in-house packed with 1.9-mm
C18 beads (Reprosil Pur-AQ, Dr Maisch) using a 3 h gradient ranging from 5 to
64% acetonitrile in 0.5% formic acid at a ﬂow rate of 200 nlmin 1. The efﬂuent
from the HPLC was directly electrosprayed into the mass spectrometer. The
Q Exactive Plus mass spectrometer was operated using data-dependent acquisition,
with all samples being analysed using a ‘sensitive’ acquisition method and a
normalized collision energy (NCE) of 28. Back-bone fragmentation of eluting
peptide species was obtained using higher-energy collisional dissociation (HCD),
which ensured high-mass accuracy on both precursor and fragment ions. All raw
data analysis was performed with MaxQuant software suite version 1.3.0.5
supported by the Andromeda search engine. For SILAC quantiﬁcation a minimum
of two ratio-counts was required.
A similar set-up was used for analysing the phosphorylated GST-Bub1 except
that an EASY-nLC 1200 UHPLC system connected to an Orbitrap Q-Exactive HF
was used and the acetonitrile gradient was run for 77min. The samples were
analysed using a ‘fast’ acquisition mode with a normalized collision energy (NCE)
of 25 and raw data analysed with MaxQuant software suit version 1.5.7.4.
Circular dichroism. Circular dichroism spectra were recorded at 20 C in a
Jasco J-815 spectropolarimeter using a 0.2 cm path length quartz cell cuvette,
260–190 nm measurement range, 50 nmmin 1 scanning speed, 2 s response time
and 0.5 nm data pitch. Peptides at 30 mM were dissolved in water or in the organic
solvent 2,2,2-triﬂuoroethanol.
Surface plasmon resonance. Bub1 peptides were purchased from Biosyntan
Gmbh (Germany). The purity obtained in the synthesis was 95–98% as determined
by high-performance liquid chromatography (HPLC) and the identity of the
peptides was conﬁrmed by mass spectrometry. SPR experiments were performed
on a Biacore T200 (GE Healthcare) at 25 C. Streptavidin (ThermoFisher Scientiﬁc)
at 0.05mgml 1 in 10mM sodium acetate, pH 4.5, was directly immobilized on a
CM5 sensor chip (GE Healthcare) by standard amine coupling chemistry with
N-hydroxysuccinimide and N-ethly-N0-(3-dimethlyaminopropyl)carbodiimide up
to an immobilization level of approximately 2000 RU. Unreacted sites were
quenched with ethanolamine HCl. Subsequently, N-terminal biotinylated Bub1
peptides (at 10 nM in HBS-EPþ buffer and ﬂow rate 5 ml min 1) were captured at
B50 RU, respectively, in channels 2, 3 and 4 of the streptavidin coated chip,
leaving channel 1 free for reference. An identical approach was used to prepare a
second CM5 chip with the negative controls. In this case, a N-terminal biotinylated
5A mutant, a non-related phosphorylated peptide and the Bub1 pT461 peptide
were captured, respectively, in channels 2, 3 and 4. HBS-EPþ (10mM Hepes, pH
7.4, 150mM NaCl, 3mM EDTA, 0.05% (v/v) Surfactant P20) was used as running
buffer for both streptavidin immobilization and peptide capture. Before the afﬁnity
measurements, both Mad1 and Mad1 RLK/AAA were extensively dialysed against
the assay running buffer 25mM Tris, pH 7.8, 150mM NaCl, 10mMMgCl2, 0.25M
TCEP, 0.005% (v/v) Surfactant P-20. Mad1 and the Mad1 RLK/AAA mutant
were injected (at a ﬂow rate of 10 ml min 1) over the sensor surfaces at eight
concentrations (starting at the lowest concentration of 3.9 mM (Mad1) or 1.95 mM
(RLK)) prepared by twofold serial dilution in assay buffer of a 500 mM (Mad1) or
250 mM (RLK) stock. The dissociation time was set-up at 180 s. Sensorgrams
were analysed after double referencing. Equilibrium was reached over the course of
the injection and the average RU values for each protein concentration at steady
state (5 s before the end of the injection) plotted against protein concentration
and ﬁtted by nonlinear regression to a steady-state afﬁnity model to determine the
dissociation constants, KDs.
Protein expression. Puriﬁed FLAG Bub1 146–553/Bub3 was obtained from
HEK293 cells by transfecting ten 15 cm dishes, 1 107 cells per dish, each with
15 mg FLAG Bub1 146–553 and 15 mg untagged Bub3 plasmids. Two days after
transfection cells were collected and FLAG Bub1 146–553/Bub3 puriﬁed by lysing
cells in buffer L (350mM NaCl, 50mM Tris pH 8.0, 0.05% NP40) and following
centrifugation the lysate was incubated with 300 ml anti-FLAG beads (Sigma).
Following washing with buffer L the Bub1 146–553/Bub3 complex was eluted with
buffer L containing 200 ng ml 1 FLAG peptide by incubating for 20min. Bub1
146–553/Bub3 was stored at 4 C.
His-Strep tagged Mad1(597–718) and His tagged Mad1(485–718)/Mad2
protein was expressed in BL21(DE3) cells at 18 C overnight with 0.5mM IPTG in
the medium. Following lysis the protein was puriﬁed on HiTrap Ni column and
eluted in buffer E (50mM NaP pH 7.5, 300mM NaCl, 500mM immidazole, 10%
glycerol, 0.5mM TCEP) and peak fractions were further puriﬁed on HiLoad 16/60
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superdex 75 column equilibrated with buffer G (50mM NaP pH 7.5, 150mM
NaCl, 10% glycerol, 0.5mM TCEP). Before the superdex 75 column the Mad1
(485–718)/Mad2 complex was run on a Mono Q 10/100 GL column and peak
fractions pooled for size exclusion. Peak fractions were aliquoted and stored at
 80 C.
GST- Bub1 (425–500) was expressed in BL21(DE3) cells at 18 C overnight with
0.5mM IPTG in the medium. The bacteria were lysed in 50mM Tris-HCl pH 7.4,
300mM NaCl, 10% glycerol, 5mM b-mercaptoethanol, 1mM PMSF, plus
Complete-EDTA free protease inhibitors (Roche) using a high pressure
homogenizer. Lysates were cleared by centrifugation and incubated with
pre-equilibrated Glutathione-Fast Flow (GE Healthcare) beads for 2 h at 4 C and
eluted with GST-elution buffer at room temperature (50mM Tris pH 8.8, 300mM
NaCl, 10% glycerol, 5mM b-mercaptoethanol, 20mM reduced glutathione).
Elutions were pooled and run on Superdex 200 column (GE Healthcare) in PBS
with 8.7% glycerol and 5mM mercaptoethanol. Peak fractions were aliquoted and
stored at  80 C.
Immunoﬂuorescence and quantiﬁcation. Cells growing on coverslips were syn-
chronized with a double thymidine block and RO3306 (10 nM) block (for Cdc20
staining only). After washing with PBS, the cells were treated with medium
containing nocodazole (200 ngml 1) for 1–2 h and ﬁxed with 4%
paraformaldehyde in PHEM buffer (60mM PIPES, 25mM HEPES, pH 6.9, 10mM
EGTA, 4mM MgSO4) for 20min at room temperature. Fixed cells were extracted
with 0.5% Triton X-100 in PHEM buffer for 10min. The antibodies used for cell
staining include Bub1 (Abcam, ab54893, 1:400), Cdc20 (Millipore, MAB3775,
1:200), CREST (Antibodies Incorporated, 15–234, 1:400) and GFP (Abcam, ab290,
1:400). Streptavidin-FITC (Sigma S3762, 1:200) was used for staining of
BirA-Mad1 or Mad1-BirA cells. The Bub1 phospho antibody was raised against a
50:50 mix of C-Ahx-PSKVQP[pS]P[pT]VHTKEA-amide and Acetyl-
SKVQP[pS]P[pT]VHTKEA-Ahx-C-amide peptides coupled to carrier and the
antibody was afﬁnity puriﬁed (21st Century Biochemicals) and used at a 1:400
dilution. All the ﬂuorescent secondary antibodies are Alexa Fluor Dyes (Invitrogen,
1:1,000). Z-stacks 200 nm apart were recorded on a Deltavision Elite microscope
(GE Healthcare) using a  100 oil objective followed by deconvolution using
Softworx before quantiﬁcation. Protein intensity on kinetochores was quantiﬁed
by drawing a circle closely along the rod-like CREST staining covering the
interested outer kinetochore protein staining on both ends. The intensity values
from the peak three continuous stacks were subtracted of the background from
neighbouring areas and averaged. The combined intensity was normalized against
the combined CREST ﬂuorescent intensity.
Immunoprecipitation and in vitro protein binding assay. HeLa cells in 15 cm
dishes were transfected with either luciferase or Bub1 RNAi oligos twice or
corresponding constructs once within 48 h. A volume of 200 ngml 1 of
nocodazole was used to arrest cells before the mitotic cells were collected and lysed
in lysis buffer containing 10mM Tris pH 7.4, 150mM NaCl, 0.5mM EDTA
and 0.5% NP-40 with both protease and phosphatase inhibitors (Roche). After
centrifugation at 17,000g for 10min, the supernatant was applied to 20 ml of
rec-Protein G sepharose beads (Thermo Fisher) beads pre-crosslinked with a pan
Mad2 antibody60 or GFP Trap beads (Chromotek) and shaken at 4 C for 2 h. After
three times of washing with 0.5ml lysis buffer, the bound protein was eluted by
boiling in 50ml 2 LDS loading buffer. Western blot was performed afterwards.
For binding experiments between Mad1 and Bub1, 8 mg of His-Strep-Mad1
597–718 was incubated with 1 mg FLAG-Bub1 146–553/Bub3 complexes in 125 ml
of binding buffer (30mM Tris pH 7.4, 50mM NaCl, 0.1mM DTT) for 30min at
30 C. The reaction was added to 20 ml Strep-Tactin beads (GE Healthcare) and
incubated an additional 45min. The beads were washed three times with 500 ml
wash buffer (30mM Tris pH 7.4, 120mM NaCl, 0.1mM DTT, 0.1% NP-40) and
then complexes eluted with 60 ml elution buffer (100mM Tris pH 8.0, 120mM
NaCl, 2.5mM desthiobiotin) for 15min. The samples were analysed by SDS–PAGE
and stained with coomasie or analysed by western blot.
The following antibodies were used for western blot: BubR1 (Rabbit polyclonal,
1:5,000, produced in house), Cdc20 (sc-13162, 1^1,000, Santa Cruz), FLAG (F3165,
1:2,000, Sigma), Ndc80 (ab3613, 1:1,000, abcam), Mad2 (A300-301A, 1:1,000,
Bethyl Laboratories), Bub1 (ab54893, 1:1,000, abcam), Bub3 (611730, 1:1,000,
BD Biosciences), Knl1 (Rabbit polyclonal, 1:500, produced in house), APC7
(A302-550A, 1:2000, Bethyl Laboratories).
In vitro phosphorylation of GST Bub1. Recombinant GST-Bub1 (12 mg) was
incubated with 20 units CDK1-CyclinB1 (New England Biolabs), 0,2 mg Mps1
(TTK; Life Technologies) in protein kinase buffer (50mM Tris pH 7.5, 10mM
MgCl2, 0.1mM EDTA, 2mM DTT, 0.01% Brij 35). 500 mM ATP and 125 nM
Calyculin A (Cell Signaling) were added and the reactions were incubated at 30 C
for 1 h. Controls were incubated in kinase buffer and Calyculin A only. 6 mg of
phosphorylated protein was resolved on NuPAGE Novex 4–12% Bis-Tris protein
gels, which were ﬁxed and stained by Colloidal Blue Staining (Thermo Scientiﬁc).
The band corresponding to GST-Bub1 was cut out and analysed by mass
spectrometry.
Live cell imaging. Live cell imaging was performed on a Deltavision Elite system
using a  40 oil objective (GE Healthcare). Cells transfected with RNAi oligos and
corresponding plasmids in a six-well plate were re-seeded in eight-well Ibidi dishes
(Ibidi) 1 day before the ﬁlming. Growth media was changed to Leibovitz´s L-15
(Life technologies) containing low dose nocodazole (30 ngml 1) before ﬁlming.
Appropriate channels were recorded for 22 h and the data were analysed using
Softworx (GE Healthcare). Statistical analysis was done using Prism software.
At least three independent experiments were performed for all live cell experiments
and the data pooled from multiple experiments are presented in ﬁgures.
Data availability. All relevant data are available from the authors upon request.
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